Utilization patterns of iv iron and erythropoiesis stimulating agents in anemic chronic kidney disease patients: A multihospital study

Anemia

Volumn 2012, Issue , 2012, Pages

  Joshi, Avani D ^a,b   Holdford, David A ^b   Brophy, Donald F ^b   Harpe, Spencer E ^b,c   Mays, Darcy ^b   Gehr, Todd W B ^b  

^a ABBOTT LABORATORIES   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873801698     PISSN: 20901267     EISSN: 20901275     Source Type: Journal    
DOI: 10.1155/2012/248430     Document Type: Article

References (54)

1. National Kidney Foundation, KDOQI clinical practice guidelines clinical practice recommendations for anemia in chronic kidney disease. American Journal of Kidney Disease 2007 50 471 530
2. McClellan W., Aronoff S. L., Bolton W. K., Hood S., Lorber D. L., Tang K. L., Tse T. F., Wasserman B., Leiserowitz M., The prevalence of anemia in patients with chronic kidney disease. Current Medical Research and Opinion 2004 20 9 1501 1510 2-s2.0-5444255241 10.1185/030079904X2763 (Pubitemid 39361354)
3. Jensen J. D., Madsen J. K., Jensen L. W., Pedersen E. B., Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. Journal of the American Society of Nephrology 1994 5 2 177 185 2-s2.0-0028490715 (Pubitemid 24977073)
4. Khan S. S., Kazmi W. H., Abichandani R., Tighiouart H., Pereira B. J., Kausz A. T., Health care utilization among patients with chronic kidney disease. Kidney International 2002 62 1 229 236 2-s2.0-0036318066 10.1046/j.1523-1755. 2002.00432.x (Pubitemid 34754066)
5. Fink J., Blahut S., Reddy M., Light P., Use of erythropoietin before the initiation of dialysis and its impact on mortality. American Journal of Kidney Diseases 2001 37 2 348 355 2-s2.0-0035147487 (Pubitemid 32116028)
6. Revicki D. A., Brown R. E., Feeny D. H., Henry D., Teehan B. P., Rudnick M. R., Benz R. L., Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. American Journal of Kidney Diseases 1995 25 4 548 554 2-s2.0-0028945387
7. Clyne N., Jogenstrand T., Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992 60 4 390 396 2-s2.0-0026523401
8. Lim V. S., DeGowin R. L., Zavala D., Kirchner P. T., Abels R., Perry P., Fangman J., Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Annals of Internal Medicine 1989 110 2 108 114 2-s2.0-0024581871 (Pubitemid 19033195)
9. Drüeke T. B., Eckardt K. U., Frei U., Jacobs C., Kokot F., McMahon L. P., Schaefer R. M., Does early anemia correction prevent complications of chronic renal failure? Clinical Nephrology 1999 51 1 1 11 2-s2.0-0344923792 (Pubitemid 29027400)
10. Nurko S., Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleveland Clinic Journal of Medicine 2006 73 3 289 297 2-s2.0-33645501811 10.3949/ccjm.73.3.289
11. Besarab A., Soman S., Anemia management in chronic heart failure: lessons learnt from chronic kidney disease. Kidney and Blood Pressure Research 2006 28 5-6 363 371 2-s2.0-33644973853 10.1159/000090191
12. Popovsky M. A., Ransil B. J., Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. Immunohematology 1996 12 1 1 3 2-s2.0-0030002368 (Pubitemid 26102951)
13. Drüeke T. B., Locatelli F., Clyne N., Eckardt K. U., Macdougall I. C., Tsakiris D., Burger H. U., Scherhag A., Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The New England Journal of Medicine 2006 355 20 2071 2084 2-s2.0-33751002326 10.1056/NEJMoa062276 (Pubitemid 44749316)
14. Singh A. K., Szczech L., Tang K. L., Correction of anemia with epoetin alfa in chronic kidney disease. The New England Journal of Medicine 2006 355 20 2085 2098 2-s2.0-33750983605 (Pubitemid 44749317)
15. Chang C. H., Chang C. C., Chiang S. S., Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clinical Nephrology 2002 57 2 136 141 2-s2.0-0036173106
16. Fishbane S., Frei G. L., Maesaka J., Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases 1995 26 6 41 46 2-s2.0-0028793934
17. Miyashita K., Tojo A., Kimura K., Goto A., Omata M., Nishiyama K., Fujita T., Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertension Research 2004 27 2 79 84 2-s2.0-1542345487 10.1291/hypres.27.79 (Pubitemid 38325178)
18. Ng T., Marx G., Littlewood T., Macdougall I., Recombinant erythropoietin in clinical practice. Postgraduate Medical Journal 2003 79 933 367 376 2-s2.0-0041660591 10.1136/pmj.79.933.367 (Pubitemid 36993965)
19. Amgen Inc, Aranesp Prescribing information 2007
20. US Food and Drug Administration, Postmarketing drug safety information for patients and providers, Approved Risk evaluation and Mitigation Strategies (REMS), 2010, http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm
21. Coyne D. W., Kapoian T., Suki W., Singh A. K., Moran J. E., Dahl N. V., Rizkala A. R., Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis Patients' response to IV iron with elevated ferritin (DRIVE) study. Journal of the American Society of Nephrology 2007 18 3 975 984 2-s2.0-33947212276 10.1681/ASN.2006091034 (Pubitemid 46434515)
22. Kapoian T., O'Mara N. B., Singh A. K., Moran J., Rizkala A. R., Geronemus R., Kopelman R. C., Dahl N. V., Coyne D. W., Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. Journal of the American Society of Nephrology 2008 19 2 372 379 2-s2.0-39049101651 10.1681/ASN.2007050606 (Pubitemid 351240658)
23. National Kidney Foundation, KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. American Journal of Kidney Disease 2006 47 5, supplement 3 S11 S145
24. DeVita M. V., Mittal S., Frumkin D., Kamran A., Fishbane S., Michelis M. F., Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clinical Nephrology 2003 60 5 335 340 2-s2.0-0242606394 (Pubitemid 37407691)
25. St Peter W. L., Obrador G. T., Roberts T. L., Collins A. J., Trends in intravenous iron use among dialysis patients in the United States (1994-2002). American Journal of Kidney Diseases 2005 46 4 650 660 2-s2.0-25644432169 10.1053/j.ajkd.2005.06.018 (Pubitemid 41383943)
26. Twisk J. W. R., Generalized Estimating Equations, Applied Longitudinal Data Analysis for Epidemiology. A practical guide, pp. 55-98, 2003
27. Norusis M. J., SPSS 16.0 Advanced Statistical Procedures Companion 2008 Upper Saddle River, NJ, USA Prentice Hall Inc
28. Bailie G. R., Eisele G., Liu L., Roys E., Kiser M., Finkelstein F., Wolfe R., Port F., Burrows-Hudson S., Saran R., Patterns of medication use in the RRI-CKD study: focus on medications with cardiovasculars effects. Nephrology Dialysis Transplantation 2005 20 1110 1115 2-s2.0-20844455116 10.1093/ndt/gfh771 (Pubitemid 40862099)
29. Rasu R. S., Manley H. J., Crawford T., Balkrishnan R., Undertreatment of anemia in patients with chronic kidney disease in the United States: analysis of national outpatient survey data. Clinical Therapeutics 2007 29 7 1524 1534 2-s2.0-34548357307 10.1016/j.clinthera.2007.07.016 (Pubitemid 47348114)
30. Payne S. M., Iron and virulence in Shigella. Molecular Microbiology 1989 3 9 1301 1306 2-s2.0-0024469919 (Pubitemid 19239974)
31. Payne S. M., Iron and virulence in the family Enterobacteriaceae. Critical Reviews in Microbiology 1988 16 2 81 111 2-s2.0-0024243440
32. Guerinot M. L., Microbial iron transport. Annual Review of Microbiology 1994 48 743 772 2-s2.0-0027945605 (Pubitemid 24334115)
33. Patruta S. I., Edlinger R., Sunder-Plassmann G., Hörl W. H., Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. Journal of the American Society of Nephrology 1998 9 4 655 663 2-s2.0-0031949458 (Pubitemid 28186054)
34. Lim P. S., Wei Y. H., Yu Y. L., Kho B., Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrology Dialysis Transplantation 1999 14 11 2680 2687 2-s2.0-0033281707 (Pubitemid 32208386)
35. Tovbin D., Mazor D., Vorobiov M., Chaimovitz C., Meyerstein N., Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. American Journal of Kidney Diseases 2002 40 5 1005 1012 2-s2.0-0036841986 10.1053/ajkd.2002.36334 (Pubitemid 35265481)
36. Zager R. A., Johnson A. C., Hanson S. Y., Wasse H., Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. American Journal of Kidney Diseases 2002 40 1 90 103 2-s2.0-0036280354 10.1053/ajkd.2002.33917 (Pubitemid 34701216)
37. Feldman H. I., Santanna J., Guo W., Furst H., Franklin E., Joffe M., Marcus S., Faich G., Iron administration and clinical outcomes in hemodialysis patients. Journal of the American Society of Nephrology 2002 13 3 734 744 2-s2.0-0036191165 (Pubitemid 34183940)
38. Feldman H. I., Joffe M., Robinson B., Knauss J., Cizman B., Guo W., Franklin-Becker E., Faich G., Administration of parenteral iron and mortality among hemodialysis patients. Journal of the American Society of Nephrology 2004 15 6 1623 1632 2-s2.0-2542429341 10.1097/01.ASN.0000128009.69594.BE (Pubitemid 38679688)
39. Polk R. E., Fox C., Mahoney A., Letcavage J., MacDougall C., Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clinical Infectious Diseases 2007 44 5 664 670 2-s2.0-33847070863 10.1086/511640
40. Shetka M., Pastor J., Phelps P., Evaluation of the defined daily dose method for estimating antiinfective use in a university hospital. American Journal of Health-System Pharmacy 2005 62 21 2288 2292 2-s2.0-27644547780 10.2146/ajhp050140 (Pubitemid 41566751)
41. Muller A., Monnet D. L., Talon D., Hénon T., Bertrand X., Discrepancies between prescribed daily doses and WHO defined daily doses of antibacterials at a university hospital. British Journal of Clinical Pharmacology 2006 61 5 585 591 2-s2.0-33646241070 10.1111/j.1365-2125.2006. 02605.x
42. Pakyz A. L., MacDougall C., Oinonen M., Polk R. E., Trends in antibacterial use in US academic health centers: 2002 to 2006. Archives of Internal Medicine 2008 168 20 2254 2260 2-s2.0-55949093232 10.1001/archinte.168. 20.2254
43. Bailie G. R., Johnson C. A., Mason N. A., Parenteral iron use in the management of anemia in end-stage renal disease patients. American Journal of Kidney Diseases 2000 35 1 1 12 2-s2.0-0033981609 (Pubitemid 30027233)
44. Robbins J. D., Kim J. J., Zdon G., Chan W. W., Jones J., Resource use and patient care associated with chronic kidney disease in a managed care setting. Journal of Managed Care Pharmacy 2003 9 3 238 247 2-s2.0-0642276792
45. John R., Webb M., Young A., Stevens P. E., Unreferred chronic kidney disease: a longitudinal study. American Journal of Kidney Diseases 2004 43 5 825 835 2-s2.0-1942530825 10.1053/j.ajkd.2003.12.046 (Pubitemid 38529620)
46. Wong C. F., McCarthy M., Howse M. L. P., Williams P. S., Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis. Renal Failure 2007 29 6 653 659 2-s2.0-34548317013 10.1080/08860220701459634 (Pubitemid 47346982)
47. Khan I. H., Catto G. R., Edward N., Fleming L. W., Henderson I. S., MacLeod A. M., Influence of coexisting disease on survival on renal-replacement therapy. The Lancet 1993 341 8842 415 418 2-s2.0-0027523123 10.1016/0140- 6736(93)93003-J (Pubitemid 23048156)
48. Davies S. J., Phillips L., Naish P. F., Russell G. I., Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrology Dialysis Transplantation 2002 17 6 1085 1092 2-s2.0-0035992062 (Pubitemid 34746213)
49. Charlson M. E., Pompei P., Ales K. L., MacKenzie C. R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987 40 5 373 383 2-s2.0-0023092594 (Pubitemid 17055592)
50. van Manen J. G., van Dijk P. C., Stel V. S., Dekker F. W., Clèries M., Conte F., Feest T., Kramar R., Leivestad T., Briggs J. D., Stengel B., Jager K. J., Confounding effect of comorbidity in survival studies in patients on renal replacement therapy. Nephrology Dialysis Transplantation 2007 22 1 187 195 2-s2.0-33846000635 10.1093/ndt/gfl502 (Pubitemid 46050344)
51. Shen Y., Applying the 3M all patient refined diagnosis related groups grouper to measure inpatient severity in the VA. Medical Care 2003 41 6 II103 II110 2-s2.0-0038202983
52. Iezzoni L. I., Shwartz M., Ash A. S., Mackiernan Y. D., Does severity explain differences in hospital length of stay for pneumonia patients? Journal of Health Services Research & Policy 1996 1 2 65 76 2-s2.0-0030112180
53. Shwartz M., Iezzoni L. I., Ash A. S., Mackiernan Y. D., Do severity measures explain differences in length of hospital stay? The case of hip fracture. Health Services Research 1996 31 4 365 385 2-s2.0-0029864559 (Pubitemid 26359155)
54. Jefferies L., Smith M. E., Magee D., Wallace P., Horgan M., A team approach to decrease wasted blood products. Laboratory Medicine 1996 27 12 833 839 2-s2.0-0029965613 (Pubitemid 26396863)